NEO 6860

Drug Profile

NEO 6860

Alternative Names: NEO6860; TRPV1 antagonist - NEOMED; Vanilloid receptor 1 ion channel antagonist - NEOMED

Latest Information Update: 24 Jul 2016

Price : $50

At a glance

  • Originator AstraZeneca Canada
  • Developer NEOMED
  • Class Analgesics; Antirheumatics; Benzimidazoles; Small molecules
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Musculoskeletal pain; Neuropathic pain; Visceral pain

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Neuropathic pain; Visceral pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Visceral-pain in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (PO)
  • 11 May 2016 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial (In volunteers) presented at the 35th Annual Scientific Meeting of the American Pain Society (APS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top